Nephros Q4 2023 GAAP EPS $(0.060) Misses $(0.030) Estimate, Sales $3.300M Miss $3.813M Estimate

3/7/24 4:42:25 PM ET

Medical/Dental Instruments

Health Care

Get the next $NEPH alert in real time by email

Nephros (NASDAQ:NEPH) reported quarterly losses of $(0.060) per share which missed the analyst consensus estimate of $(0.030) by 100 percent. The company reported quarterly sales of $3.300 million which missed the analyst consensus estimate of $3.813 million by 13.47 percent. This is a 29.01 percent increase over sales of $2.558 million the same period last year.

Get the next $NEPH alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NEPH

Date	Price Target	Rating	Analyst

More analyst ratings

$NEPH
Leadership Updates

Live Leadership Updates

Nephros Hires Judy Krandel as Chief Financial Officer
SOUTH ORANGE, NJ, Nov. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, announced the appointment of Judy Krandel as Chief Financial Officer (CFO), effective today. In this role, Ms. Krandel will be responsible for directing the company's finances and working closely with the Chief Executive Officer (CEO) and Board of Directors to develop and execute Nephros's long-term strategy. Ms. Krandel joins the company with an impressive track record in financial leadership and strategic planning. She brings more than 20 years of experience in asset management, inv
11/1/23 7:30:00 AM ET
$NEPH
Medical/Dental Instruments
Health Care
Nephros Appoints Joe Harris to Its Board of Directors
SOUTH ORANGE, NJ, Sept. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced the appointment of Joe Harris to its Board of Directors. "We are excited that Joe is joining our board," said Andy Astor, President and Chief Executive Officer of Nephros. "He brings years of financial, sales, and marketing acumen to the board, with experience in both large and small healthcare ventures." "I am thrilled to join the Nephros board," said Joe Harris. "I believe Nephros is at an exciting point as they continue to focus on sales moment
9/8/22 4:00:00 PM ET
$NEPH
Medical/Dental Instruments
Health Care
RION Appoints Alisa Lask as Chief Commercial Officer
- Alisa Lask to lead commercialization of the first off-the-shelf exosome therapeutic platform - Two active FDA registrations RION, a biotechnology company headquartered in Rochester, Minnesota pioneering new innovations in exosomes for therapeutic and aesthetic indications, today announced the appointment of Alisa Lask as Chief Commercial Officer. "Alisa brings an exemplary track record gained through both global and U.S. leadership roles at Galderma, Allergan, Zimmer-Biomet, and Eli Lilly and Company, showing significant capability to spearhead commercial strategies to create world-class aesthetic and therapeutic product franchises," said Dr. Atta Behfar, Founder of RION. "She has prov
1/14/22 9:00:00 AM ET
$CLGN
$NEPH
Industrial Specialties
Health Care
Medical/Dental Instruments

Nephros Announces Financial Results for Quarter Ended September 30, 2024
Third-Quarter Net Revenue of $3.5 Million;Operational Improvements Result In First Profitable Quarter SOUTH ORANGE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the third quarter ended September 30, 2024. Financial Highlights* Net income of $0.2 million, compared to a net loss of $0.2 millionAdjusted EBITDA of $295,000, compared to $11,000Net revenue of $3.5 million, an 8% increase over Q2 2024; a decrease of 6% over Q3 prior year *Stated performance is relative to same period in the prior year unless otherwise no
11/7/24 4:01:00 PM ET
$NEPH
Medical/Dental Instruments
Health Care
Nephros Schedules Third Quarter 2024 Financial Results Conference Call
SOUTH ORANGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions for both healthcare and commercial markets, today announced that it will file its third-quarter financial results on Thursday, November 7, 2024 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows:Domestic access: 1 (844) 808-7106International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternatively, a repl
10/31/24 7:30:00 AM ET
$NEPH
Medical/Dental Instruments
Health Care
Nephros Announces Financial Results for Quarter Ended June 30, 2024
Second-Quarter Net Revenue of $3.3 Million; New Accounts Help Drive Growth in Core Programmatic Business SOUTH ORANGE, NJ, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the second quarter ended June 30, 2024. Financial Highlights* Net revenue of $3.3 million, a decrease of 8% over Q2 prior year; programmatic revenue (excluding emergency response revenue) increased 8% over Q2 prior yearNet loss of $0.3 million, compared to a net loss of $0.4 millionAdjusted EBITDA of ($133,000), compared to ($183,000) *Stated performance
8/8/24 4:01:00 PM ET
$NEPH
Medical/Dental Instruments
Health Care

$NEPH
Press Releases

Fastest customizable press release news feed in the world

Nephros Announces Financial Results for Quarter Ended September 30, 2024
Third-Quarter Net Revenue of $3.5 Million;Operational Improvements Result In First Profitable Quarter SOUTH ORANGE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the third quarter ended September 30, 2024. Financial Highlights* Net income of $0.2 million, compared to a net loss of $0.2 millionAdjusted EBITDA of $295,000, compared to $11,000Net revenue of $3.5 million, an 8% increase over Q2 2024; a decrease of 6% over Q3 prior year *Stated performance is relative to same period in the prior year unless otherwise no
11/7/24 4:01:00 PM ET
$NEPH
Medical/Dental Instruments
Health Care
Nephros Schedules Third Quarter 2024 Financial Results Conference Call
SOUTH ORANGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions for both healthcare and commercial markets, today announced that it will file its third-quarter financial results on Thursday, November 7, 2024 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows:Domestic access: 1 (844) 808-7106International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternatively, a repl
10/31/24 7:30:00 AM ET
$NEPH
Medical/Dental Instruments
Health Care
Nephros Launches New HydraGuard 20" UltraFilter
New Filter Targets Additional Industries and Water Quality Compliance SOUTH ORANGE, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH) Nephros, Inc., a leader in advanced filtration technology, is excited to announce the release of the HydraGuard 20" UltraFilter. This latest innovation enables the company to break into new markets and aid in compliance with water quality standards such as ANSI/AAMI ST108. The HydraGuard 20" model is an extension of the existing HydraGuard and designed to provide a higher-volume capacity and flow rate, while removing harmful contaminants like bacteria, viruses, and endotoxins. With this product, Nephros is poised to serve a broader ran
10/24/24 9:00:00 AM ET
$NEPH
Medical/Dental Instruments
Health Care

Nephros Q4 2023 GAAP EPS $(0.060) Misses $(0.030) Estimate, Sales $3.300M Miss $3.813M Estimate

Chat with this insight

Recent Analyst Ratings for $NEPH

$NEPH Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

B. Riley FBR initiated coverage on Nephros with a new price target

$NEPH Leadership Updates

Live Leadership Updates

Nephros Hires Judy Krandel as Chief Financial Officer

Nephros Appoints Joe Harris to Its Board of Directors

RION Appoints Alisa Lask as Chief Commercial Officer

$NEPH Financials

Live finance-specific insights

$NEPH Market Insights

Live Market Insights

$NEPH SEC Filings

$NEPH Large Ownership Changes

This live feed shows all institutional transactions in real time.

Nephros Announces Financial Results for Quarter Ended September 30, 2024

Nephros Schedules Third Quarter 2024 Financial Results Conference Call

Nephros Announces Financial Results for Quarter Ended June 30, 2024

GEE Group And 2 Other Stocks Under $3 Insiders Are Buying

Benchmark Reiterates Speculative Buy on Nephros, Maintains $5 Price Target

Nephros Files For Mixed Shelf Of Up To $50M

Nephros Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by Nephros Inc.

SEC Form S-8 filed by Nephros Inc.

SEC Form SC 13G filed by Nephros Inc.

SEC Form SC 13G filed by Nephros Inc.

SEC Form SC 13G filed by Nephros Inc.

$NEPH Press Releases

Fastest customizable press release news feed in the world

Nephros Announces Financial Results for Quarter Ended September 30, 2024

Nephros Schedules Third Quarter 2024 Financial Results Conference Call

Nephros Launches New HydraGuard 20" UltraFilter

$NEPH Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Amron Arthur H bought $11,176 worth of shares (5,000 units at $2.24), increasing direct ownership by 5% to 103,463 units (SEC Form 4)

Banks Robert R. Jr. bought $112,050 worth of shares (50,000 units at $2.24), increasing direct ownership by 250% to 70,000 units (SEC Form 4)

SEC Form 4 filed by Amron Arthur H

$NEPH Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Amron Arthur H bought $11,176 worth of shares (5,000 units at $2.24), increasing direct ownership by 5% to 103,463 units (SEC Form 4)

Banks Robert R. Jr. bought $112,050 worth of shares (50,000 units at $2.24), increasing direct ownership by 250% to 70,000 units (SEC Form 4)

Amron Arthur H bought $17,130 worth of shares (7,000 units at $2.45) and acquired 91,463 shares (SEC Form 4)

Recent Analyst Ratings for
$NEPH

$NEPH
Analyst Ratings

$NEPH
Leadership Updates

$NEPH
Financials

$NEPH
Market Insights

$NEPH
SEC Filings

$NEPH
Large Ownership Changes

$NEPH
Press Releases

$NEPH
Insider Trading

$NEPH
Insider Purchases